1. Home
  2. LPCN vs MXC Comparison

LPCN vs MXC Comparison

Compare LPCN & MXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LPCN
  • MXC
  • Stock Information
  • Founded
  • LPCN 1997
  • MXC 1972
  • Country
  • LPCN United States
  • MXC United States
  • Employees
  • LPCN N/A
  • MXC N/A
  • Industry
  • LPCN Biotechnology: Pharmaceutical Preparations
  • MXC Oil & Gas Production
  • Sector
  • LPCN Health Care
  • MXC Energy
  • Exchange
  • LPCN Nasdaq
  • MXC Nasdaq
  • Market Cap
  • LPCN 18.2M
  • MXC 18.4M
  • IPO Year
  • LPCN N/A
  • MXC N/A
  • Fundamental
  • Price
  • LPCN $3.19
  • MXC $9.29
  • Analyst Decision
  • LPCN Strong Buy
  • MXC
  • Analyst Count
  • LPCN 1
  • MXC 0
  • Target Price
  • LPCN $8.00
  • MXC N/A
  • AVG Volume (30 Days)
  • LPCN 45.3K
  • MXC 4.5K
  • Earning Date
  • LPCN 11-06-2025
  • MXC 11-06-2025
  • Dividend Yield
  • LPCN N/A
  • MXC 1.08%
  • EPS Growth
  • LPCN N/A
  • MXC 44.21
  • EPS
  • LPCN N/A
  • MXC 0.79
  • Revenue
  • LPCN $4,208,119.00
  • MXC $7,444,407.00
  • Revenue This Year
  • LPCN N/A
  • MXC N/A
  • Revenue Next Year
  • LPCN N/A
  • MXC N/A
  • P/E Ratio
  • LPCN N/A
  • MXC $11.35
  • Revenue Growth
  • LPCN N/A
  • MXC 13.06
  • 52 Week Low
  • LPCN $2.65
  • MXC $5.89
  • 52 Week High
  • LPCN $6.17
  • MXC $16.00
  • Technical
  • Relative Strength Index (RSI)
  • LPCN 63.61
  • MXC 52.80
  • Support Level
  • LPCN $2.65
  • MXC $8.42
  • Resistance Level
  • LPCN $3.52
  • MXC $9.46
  • Average True Range (ATR)
  • LPCN 0.16
  • MXC 0.41
  • MACD
  • LPCN 0.06
  • MXC -0.03
  • Stochastic Oscillator
  • LPCN 67.24
  • MXC 54.89

About LPCN Lipocine Inc.

Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

About MXC Mexco Energy Corporation

Mexco Energy Corporation is an independent oil and gas company. It is engaged in the acquisition, exploration, development, and production of natural gas and crude oil properties located in the United States. The company carried out its operation in the Permian Basin of West Texas. It is focusing on two primary areas, the Delaware Basin located in the Western portion of the Permian Basin including Lea and Eddy Counties, New Mexico and Loving County, Texas, and the Midland Basin located in the Eastern portion of the Permian Basin including Reagan, Upton, Midland, Martin, Howard, and Glasscock Counties, Texas. The company generates revenue from Oil sales, Natural gas sales, oil and gas royalty interests.

Share on Social Networks: